Global Biosimulation Market 2014-2018

DUBLIN, April 17, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3wgkr8/global) has announced the addition of the "Global Biosimulation Market 2014-2018" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


The analysts forecast the Global Biosimulation market to grow at a CAGR of 18.31 percent over the period 2013-2018. One of the key factors contributing to this market growth is the reduction in drug discovery and development costs, owing to the deployment of biosimulation solutions. The Global Biosimulation market has also been witnessing increasing collaborations and partnerships. However, issues associated with the accuracy in prediction, could pose a challenge to the growth of this market. 

The report, the Global Biosimulation Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, the APAC region, and the ROW; it also covers the Global Biosimulation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods. 

Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer's researchers worldwide.

According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs. 

Key Topics Covered: 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Application

08. Market Segmentation by Approach to Model Development

09. Market Segmentation by Scale of Biosimulation

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series


Companies Mentioned:

• Accelrys Inc.
• Advanced Chemistry Development Inc.
• Archimedes Inc.
• Bayer Technology Services
• Biomed Simulation Inc.
• Certara L.P.
• Chemical Computing Group Inc.
• Compugen Ltd.
• Entelos Inc.
• Genedata AG
• INOSIM Software GmbH
• Immunetrix Inc.
• In Silico Biosciences Inc.
• InhibOx Ltd.
• Insilico Biotechnology AG
• LeadInvent Technologies Pvt. Ltd.
• Leadscope Inc.
• Molecular Knowledge Systems Inc.
• Nimbus Discovery Llc
• OpenEye Scientific Software Inc.
• Optimata Inc.
• Physiomics Plc
• Rhenovia Pharma SAS
• Schrodinger Llc. and Simulation Plus Inc.
• Synergix Ltd.
• Vascular Sciences.

For more information visit http://www.researchandmarkets.com/research/3wgkr8/global

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets